Peripheral TMD Pain Mechanisms and the Effect by Botulinum Toxin A

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514739-12-00

Acronym

BTXclintrialv1

Enrollment

Registered

2024-06-20

Start date

Unknown

Completion date

Unknown

Last updated

2024-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myogenous temporomandibular disorders (TMDM)

Brief summary

The change of gene expressions, epigenetic signatures, and cells plasticity in the masseter muscle

Detailed description

The change of jaw muscle pain intensity after treatment

Interventions

DRUGBOTULINUM TOXIN

DRUG-

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
The change of gene expressions, epigenetic signatures, and cells plasticity in the masseter muscle	—

Secondary

Measure	Time frame
The change of jaw muscle pain intensity after treatment	—

Countries

Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026